central nervous system

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).

central nervous system diseases

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.

cytokines

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. WO2006/092622A1.

medical use

University of Greenwich, Old Royal Naval College Park Row, Greenwich, London SE10 9LS (2008) New medical use of triazine derivatives. WO/2008/007149.

multiple sclerosis

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).

BTG International Limited (2010) Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. PT1853254 (E).

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

neurodegeneration

BTG International Ltd. (2011) Treatment of neurodegenerative conditions. EP2324828 (A1).

neurodegenerative diseases

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. PCT/GB2006/000778.

phospholipids

BTG International Limited (2006) Structured phospholipids. WO2006/056783 A2.

polyunsaturated fatty acids

BTG International Limited (2010) Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. PT1853254 (E).

BTG International Ltd (2010) Treatment of neurodegenerative conditions. US2010/0113810 A1.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. PCT/GB2006/000778.

sodium channel blockers

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.

structured phospholipids

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

treatment of multiple sclerosis

BTG International Ltd (2010) Treatment of neurodegenerative conditions. US2010/0113810 A1.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. WO2006/092622A1.

BTG International Limited (2006) Structured phospholipids. WO2006/056783 A2.

BTG International Limited (2005) Treatment of neurodegenerative conditions. WO2005/018632/A1.

triazines

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.

University of Greenwich, Old Royal Naval College Park Row, Greenwich, London SE10 9LS (2008) New medical use of triazine derivatives. WO/2008/007149.